AstraZeneca ($AZN) announced a partnership with Daiichi Sankyo to sell its opioid-induced constipation therapy Movantik in the U.S. for a $200 million upfront fee from the Japanese drugmaker followed by sales-related payments of up to $625 million. AstraZeneca will be responsible for manufacturing and make commission payments to Daiichi Sankyo, which plans to launch the treatment in the U.S. in early April 2015 after Movantik was approved by the U.S. FDA in September last year. Release